eligibility_summary
Adults 18–65 with relapsed/refractory CD147+ T‑cell lymphomas (PTCL‑NOS, AITL, ALCL, etc.) after ≥2 lines, ECOG 0–2, adequate organ function (incl. O2 sat ≥92%), survival ≥3 mo, eligible for and agree to sequential allo‑HSCT with donor, contraception and consent required. Exclude: other cancer <5y, prior allo/organ transplant, marrow or CNS disease, pregnancy, active infections (HBV/HCV/HIV/CMV), recent steroids, prior gene therapy, lung infection, allergy, or per PI.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CD147-CAR T cells—an autologous, gene‑engineered chimeric antigen receptor T‑cell therapy. Mechanism: Patient T cells are modified ex vivo to express a CAR that binds CD147 on tumor cells, triggering antigen‑specific T‑cell activation and cytotoxic killing. Study uses dose escalation (0.1–2.0×10^6 CAR T cells/kg). Targets: CD147‑positive malignant T cells in relapsed/refractory T‑cell non‑Hodgkin’s lymphoma. Pathways engaged: CAR signaling (via CD3ζ and costimulatory domains inherent to CAR constructs) leading to T‑cell–mediated lysis/apoptosis of CD147‑expressing cells. Primary aim: assess safety and preliminary efficacy, sequential allogeneic HSCT is planned per protocol.